FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:2397-2399 December 6, 2007 Number 23 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Falutz, J. PubMed Citation

Patients with human immunodeficiency virus (HIV) infection often have a reduced mass of skeletal muscle and bone and a maldistribution of body fat. Loss of muscle mass, strength, and function are integral to the AIDS wasting syndrome and are associated with resistance to the anabolic effects of growth hormone. Administration of growth hormone in relatively high daily doses for 12 weeks improves muscle mass, strength, and function but leads to excess salt and water retention, the carpal tunnel syndrome, glucose intolerance, and insulin resistance, whereas the use of somewhat lower doses or an alternate-day regimen elicits similar beneficial effects with . . . [Full Text of this Article]

Source Information

From the Research Service, Veterans Affairs Medical Center, Washington, DC.

This article has been cited by other articles:

• (2007). A Potential Treatment for HIV-Related Abdominal Obesity. AIDS Clin Care 2007: 2-2 [Full Text]  
• (2007). Treating HIV Lipodystrophy: A Promising New Approach. JWatch Infect. Diseases 2007: 6-6 [Full Text]